Medipure Pharmaceuticals |

In the News

May 19, 2021
Medipure Holdings Inc. Announces a Filing of its Provisional Patent for Psoriasis Treatment
Vancouver, Canada (May 19, 2021) – Medipure Pharmaceuticals Inc. (“MPI”), a wholly owned subsidiary of Medipure Holdings Inc. (together with MPI, “Medipure” or the “Company”), a biopharmaceutical incubator committed to discovering and developing proprietary prescription drugs focused on the endocannabinoid system, is pleased to announce the submission of provisional patent application to the United States Patent and Trademark Office (“USPTO”) for MP-30X technology entitled “METHODS TO PRODUCE NOVEL FORMULATIONS TO TREAT INFLAMMATORY SKIN CONDITIONS” US 63/179,075 with a filing date of April 23, 2021. This invention relates to a novel topical/dermal formulation for the treatment of inflammatory skin diseases including psoriasis, psoriatic arthritis and atopic dermatitis.
Read More
Mar 16, 2021
Medipure Holdings Inc. Announces Walter Berukoff to Serve as Special Advisor to Company’s Board of Directors
Vancouver, Canada (March 16, 2021) – Medipure Holdings Inc. announces Walter Berukoff, President of Red Lion Management and Chairman and CEO of Lion One Metals Ltd., will serve as Special Advisor to the Company’s Board of Directors. For over fifty years, Mr. Berukoff has built a solid reputation as a successful mining entrepreneur, fund and money manager, real estate developer, organic agriculture enthusiast and financier. His half century of business success has earned him lasting respect for his varied accomplishments. He will draw on his expertise and support the Board as it pertains to global banking, institutional, sovereign and family offices.
Read More
Feb 25, 2021
Medipure Holdings Inc. Announces a Milestone for its Proprietary Anxiety and Mood Disorder Medication
Vancouver, Canada (February 25, 2021) – Medipure Pharmaceuticals Inc. (“MPI”), a wholly owned subsidiary of Medipure Holdings Inc. (together with MPI, “Medipure” or the “Company”), announces its anxiety and mood disorder drug (MP-20X, U.S. patent applications 20200253947 and 20200253948) has been issued a Notice of Allowance (“NOA”) from the United States Patent and Trademark Office (“USPTO”). As stated in the NOA, MP-20X “has been examined and is allowed for issuance as a patent. Prosecution on the merits is closed”.
Read More
Feb 23, 2021
Medipure Holdings Inc. Announces Denis J. Gallagher to Join Company’s Board of Directors
Vancouver, Canada (February 24, 2021) – Medipure Holdings Inc., announces Denis J. Gallagher, CEO of Economic Transformation Technologies (ETT), to join its Board of Directors. Gallagher the former Founder, Chairman and CEO of Student Transportation Inc. (STB:TSX), a publicly listed transportation and logistics company based in Toronto and New Jersey, listed on the Toronto Stock Exchange in 2004 and saw a 2011 listing on the NASDAQ prior to an April 2018 go-private sale to the Caisse de dépôt et placement in Quebec its largest shareholder. In addition to his leadership skills, Gallagher brings experience in business development, corporate governance and accessing public capital markets, to assist with the future growth plans for Medipure.
Read More
Feb 01, 2021
THE ENDOCANNABINOID SYSTEM A PHYSICIANS PERSPECTIVE
Most physicians are constantly learning not only for their benefit but, more importantly, for the benefit of their patients. It is not surprising therefore that there is considerable interest in the endocannabinoid system (ECS) as this system has only been recently recognized and appreciated. I think it is fair to say that over the last decade there has been more interest in the ECS than any other system in our body and understanding this system has generated an awareness of therapeutic potentials in many health-related areas.
Read More

Homepage

Mission

Significantly improve quality of patients' lives through development of safe and effective endocannabinoid-based therapeutics.

Vision

To be the leaders in need-driven endocannabinoid system-based prescription medication development.

Goal

To develop proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms.

Our Focus

Medipure Pharmaceuticals is a biopharmaceutical company conducting pioneering research in prescription pharmaceuticals. We are specifically focused on developing and marketing these propriety therapeutics for targeted diseases.

Pain Management
Affective disorders
Nausea and appetite
Palliative care
Oncology
Arthritis
Dermatology